Biotechnology companyCompass Pathways plc (Nasdaq: CMPS) announced on Monday that it has successfully met the primary endpoint in its Phase 3 COMP005 trial evaluating COMP360, a proprietary synthetic psilocybin, for treatment-resistant depression (TRD). A single 25 mg dose of COMP360 produced a statistically significant and clinically meaningful reduction in depression symptoms compared to placebo, with a mean difference of -3.6 on the Montgomery-Åsberg Depression Rating Scale (p
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
Oxurion signs LOI to acquire majority stake in preclinical microbiology CRO
Ritedose unveils new distribution and logistics facility
IMUNON unveils promising Phase 2 translational data for IMNN-001 in advanced ovarian cancer